ABOLERIS PHARMA ANNOUNCES €27.3 MILLION IN SERIES A FINANCING TO ADVANCE ITS NOVEL TREATMENT PARADIGM FOR AUTOIMMUNE AND INFLAMMATORY DISEASES
AbolerIS Pharma (“AbolerIS”), a biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3 million Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with participation from SFPI-FPIM, WE, Sambrinvest, Investsud Tech, and Relyens Innovation Santé/Turenne […]
Continue Reading